William Blair & Company’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

William Blair & Company’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-747	Closed	-$16.7K	–	1861
2022 Q4	$16.7K	Hold	747	–	–	﹤0.01%	1694
2022 Q3	$15K	Hold	747	–	–	﹤0.01%	1719
2022 Q2	$17K	Buy	747 +1	+0.1%	+$24	﹤0.01%	1742
2022 Q1	$20K	Hold	746	–	–	﹤0.01%	1795
2021 Q4	$27K	Hold	746	–	–	﹤0.01%	1832
2021 Q3	$31K	Sell	746 -724	-49%	-$30.6K	﹤0.01%	1733
2021 Q2	$59K	Sell	1,470 -862	-37%	-$32.2K	﹤0.01%	1672
2021 Q1	$83K	Hold	2,332	–	–	﹤0.01%	1616
2020 Q4	$73K	Buy	2,332 +20	+0.9%	+$609	﹤0.01%	1580
2020 Q3	$64K	Buy	+2,312	New	+$68K	﹤0.01%	1478

Other funds holding GERM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

William Blair & Company's GERM Position: Q1 2023 in Review

William Blair & Company sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2023, closing a stake of 747 shares — an estimated $16.7K sold.

William Blair & Company first reported a position in GERM in Q3 2020 and held it in 10 quarters. The position peaked at $83K in Q1 2021. 19 funds tracked by Wall St. Rank hold GERM as of Q1 2023.

William Blair & Company reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2023 after selling out during the quarter.
William Blair & Company sold 747 Amplify Treatments, Testing and Advancements ETF shares in Q1 2023, an estimated $16.7K.
William Blair & Company first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 10 quarters.
William Blair & Company's Amplify Treatments, Testing and Advancements ETF position peaked at $83K in Q1 2021.
19 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2023.

Based on William Blair & Company's 13F filing for Q1 2023, filed 12 May 2023.